Search results
Showing 121 to 135 of 178 results for pembrolizumab
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued Reference number: GID-TA11020
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 674. People already taking pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable through the Cancer Drugs Fund can continue. For those people, it will be funded by the company until they and their doctor decide when best to stop.
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Discontinued Reference number: GID-TA10851
In development Reference number: GID-TA10780 Expected publication date: TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Discontinued Reference number: GID-TA11004
Discontinued Reference number: GID-TA10880
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) for treating metastatic colorectal cancer after 2 systemic treatments in adults.
In development Reference number: GID-TA11093 Expected publication date: TBC
Discontinued Reference number: GID-TA11005
Discontinued Reference number: GID-TA10766
In development Reference number: GID-TA10747 Expected publication date: TBC
Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.
Fruquintinib for previously treated metastatic colorectal cancer (TA1079)
Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.